Table 2 Clinical details of these breast cancer patients.
Characteristic | (n = 108) | |
|---|---|---|
Age | 60 ± 14 | |
Type of surgery | Breast-conserving surgery | 71 (65.7%) |
Mastectomy | 37 (34.3%) | |
Histological type | Invasive carcinoma NST | 74 (68.5%) |
Lobular | 4 (3.7%) | |
Mucinous | 8 (7.4%) | |
Intraductal | 20 (18.5%) | |
Others | 2 (1.9%) | |
Estrogen receptor status | Negative | 18 (16.7%) |
Positive | 90 (83.3%) | |
Progesterone receptor status | Negative | 25 (23.1%) |
Positive | 83 (76.9%) | |
Her2 status | Negative | 69 (78.4%) |
Positive | 19 (21.6%) | |
Pathological T classification | T0 | 3 (2.8%) |
Tis | 20 (18.5%) | |
T1 | 68 (62.9%) | |
T2 | 15 (13.9%) | |
T4 | 2 (1.9%) | |
Pathological N classification | N0 | 90 (83.3%) |
N0(i+) | 1 (0.9%) | |
N1mi | 4 (3.7%) | |
N1a | 10 (9.3%) | |
N2a | 3 (2.8%) | |
Lymphatic invasion | No | 49 (45.4%) |
Yes | 59 (54.6%) | |
Vessel invasion | No | 93 (86.1%) |
Yes | 15 (13.9%) | |
Pathological staging | 0 | 23 (21.3%) |
I | 59 (54.6%) | |
II | 21 (19.5%) | |
III | 5 (4.6%) | |
Chemotherapy | No | 76 (70.4%) |
Yes | 32 (29.6%) | |
Hormone treatment | No | 29 (26.9%) |
Yes | 79 (73.1%) | |
Radiotherapy | No | 48 (44.4%) |
Yes | 60 (55.6%) | |
Neoadjuvant Chemotherapy | No | 99 (91.7%) |
Yes | 9 (8.3%) |
